FDA approves 9-valent HPV vaccine to prevent certain cancers
the ONA take:
Merck & Co., Inc. has announced that the U.S. Food and Drug Administration has approved Gardasil 9, a 9-valent human papillomavirus (HPV) recombinant vaccine for the prevention of anal, cervical, vaginal, and vulvar cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. It is also approved for the prevention of gential warts caused by HPV types 6 and 11.
The FDA approved Gardasil 9 for use in females aged 9 to 26 years and males aged 9 to 15 years. The original Gardasil vaccine only protects against types 6, 11, 16, and 18, while the new vaccine helps to protect against five additional strains.
The approval is based on a controlled trial involving about 14,000 females aged 16 to 26 years who were negative for any HPV subtypes covered by Gardasil or Gardasil 9. Patients were randomly assigned to receive Gardasil or Gardasil 9.
Results showed that Gardasil 9 was 97% more effective than Gardasil at preventing cervical, vaginal, and vulvar cancer caused by HPV types 31, 33, 45, 52, and 58, and was as effective as Gardasil at preventing diseases caused by HPV types 6, 11, 16, and 18.
Like Gardasil, Gardasil 9 is administered to patients as three separate injections, with the second administered 2 months after the first, and the third administered 4 months after that.
The FDA has approved Gardasil 9 for the prevention of anal, cervical, vaginal, and vulvar cancers.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including Informal Caregivers of Elderly in Discharge Process Reduces Readmission Risk
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|